Continued Success of Venetoclax in t(11;14) Multiple Myeloma Despite Negative Trials

Continued Success of Venetoclax in t(11;14) Multiple Myeloma Despite Negative Trials

The June Hot Topics focuses on the challenges venetoclax regimens have faced in multiple myeloma trials.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncology (Williston Park, N.Y.) N.Y.), 2024-06, Vol.38 (6), p.239-241
Hauptverfasser: Avigan, Zachary M, Joshua Richter Md
Format: Artikel
Sprache:eng
Schlagworte:
Amyloidosis
Anemia
Antimitotic agents
Antineoplastic agents
Antineoplastic Agents - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Blood cancer
Bridged Bicyclo Compounds, Heterocyclic - therapeutic use
Chromosomes, Human, Pair 11 - genetics
Chromosomes, Human, Pair 14 - genetics
Clinical Trials as Topic
Cytogenetics
Disease prevention
FDA approval
Humans
Infections
Lymphomas
Mortality
Multiple myeloma
Multiple Myeloma - drug therapy
Multiple Myeloma - genetics
Neutropenia
Pneumonia
Sepsis
Sulfonamides - administration & dosage
Sulfonamides - therapeutic use
Targeted cancer therapy
Thrombocytopenia
Translocation, Genetic
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The June Hot Topics focuses on the challenges venetoclax regimens have faced in multiple myeloma trials.
ISSN:0890-9091
DOI:10.46883/2024.25921023